Young CAR-T cells are able to persist long-term in vivo, generating a pool of CD44+CD62L+TCF1+ CAR-T cells in the spleen that can potentially generate tumor-specific TEM cells that can migrate to the tumor microenvironment (TME). The gene discussed is SELL; the disease is neoplasm.